Обзор рекомендаций по лечению АНЦА-ассоциированных системных васкулитов, представленных в 2021 г. Американской коллегией ревматологов и Фондом васкулитов

Системные васкулиты (СВ), ассоциированные с антинейтрофильными цитоплазматическими антителами (АНЦА), относятся к тяжелым жизнеугрожающим аутоиммунным заболеваниям и остаются одной из важнейших проблем практической ревматологии. В статье обсуждаются новые рекомендации Американской коллегии ревматологов и Фонда васкулитов по лечению пациентов с АНЦА-СВ, включая гранулематоз с полиангиитом (ГПА), микроскопический полиангиит (МПА) и эозинофильный гранулематоз с полиангиитом (ЭГПА), которые были опубликованы в августе 2021 г. Они включают 26 рекомендаций и 5 дополнений для ГПА/МПА, а также 15 рекомендаций и 5 дополнений для ЭГПА, которые стали основанием для предложенных алгоритмов лечения пациентов с ГПА/МПА и ЭГПА. Особое внимание уделяется применению генно-инженерных биологических препаратов.

1. Chung SA, Langford CA, Maz M, Abril A, Gorelik M, Guyatt G, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol. 2021;73(8):1366-1383. doi: 10.1002/art.41773

2. Guillevin L, Pagnoux C, Seror R, Mahr A, Mouthon L, Toumelin PL; French Vasculitis Study Group (FVSG). The Five-Factor Score revisited: Assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine (Baltimore). 2011;90(1):19-27. doi: 10.1097/MD.0b013e318205a4c6

3. Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, et al.; RAVE-ITN Research Group. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363(3):221-232. doi: 10.1056/NEJMoa0909905

4. Jones RB, Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, et al.; European Vasculitis Study Group. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med. 2010;363(3):211-220. doi: 10.1056/NEJMoa0909169

5. Kahn JE, Grandpeix-Guyodo C, Marroun I, Catherinot E, Mellot F, Roufosse F, et al. Sustained response to mepolizumab in refractory Churg - Strauss syndrome. J Allergy Clin Immunol. 2010;125(1):267-270. doi: 10.1016/j.jaci.2009.10.014

6. Wechsler ME, Akuthota P, Jayne D, Khoury P, Klion A, Langford CA, et al. Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis. N Engl J Med. 2017;376(20):1921-1932. doi: 10.1056/NEJMoa1702079

7. Menditto VG, Rossetti G, Olivari D, Angeletti A, Rocchi M, Gabrielli A, et al. Rituximab for eosinophilic granulomatosis with polyangiitis: A systematic review of observational studies. Rheumatol. 2021;60:1640-1650. doi: 10.1093/rheumatology/keab046

8. Akiyama M, Kaneko Y, Takeuchi T. Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis: A systematic literature review. Autoimmun Rev. 2021;20:102737. doi: 10.1016/j.autrev.2020.102737

9. Walsh M, Merkel PA, Peh CA, Szpirt WM, Putehal X, Fujimoto S, et al. Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis. N Engl J Med. 2020;382:622-631. doi: 10.1056/NEJMoa1803537

10. Jayne DR, Gaskin G, Rasmussen N, Abramowicz D, Ferrario F, Guillevin L, et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol. 2007;18:2180-2188. doi: 10.1681/ASN.2007010090

11. Walsh M, Casian A, Flossmann O, Westman K, Hoglund P, Pusey C, et al.; European Vasculitis Study Group (EUVAS). Long-term follow-up of patients with severe ANCA-associated vasculitis comparing plasma exchange to intravenous methylprednisolone treatment is unclear. Kidney Int. 2013;84(2):397-402. doi: 10.1038/ki.2013.131

12. Teixeira V, Mohammad AJ, Jones RB, Smith R, Jayne D. Efficacy and safety of rituximab in the treatment of eosinophilic granulomatosis with polyangiitis. RMD Open. 2019;5(1):e000905. doi: 10.1136/rmdopen-2019-000905

13. Crickx E, Machelart I, Lazaro E, Kahn JE, Cohen-Aubart F, Martin T, et al. Intravenous immunoglobulin as an immunomodulating agent in antineutrophil cytoplasmic antibody-associated vas-culitides: A French nationwide study of ninety-two patients. Arthritis Rheumatol. 2016;68:702-712. doi: 10.1002/art.39472

14. De Groot K, Rasmussen N, Bacon PA, Tervaert JW, Feighery C, Gregorini G, et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2005;52:2461-2469. doi: 10.1002/art.21142

15. Guillevin L, Pagnoux C, Karras A, Khouatra C, Aumaitre O, Cohen P, et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med. 2014;371:1771-1780. doi: 10.1056/NEJMoa1404231

16. Pagnoux C, Mahr A, Hamidou MA, Boffa JJ, Ruivard M, Ducroix JP, et al. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med. 2008;359:2790-2803. doi: 10.1056/NEJMoa0802311

17. Hiemstra TF, Walsh M, Mahr A, Savage CO, de Groot K, Harper L, et al. Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: A randomized controlled trial. JAMA. 2010;304:2381-2388. doi: 10.1001/jama.2010.1658

18. Puéchal X, Pagnoux C, Baron G, Quémeneur T, Néel A, Agard C, et al. Adding azathioprine to remission-induction glucocorticoids for eosinophilic granulomatosis with polyangiitis (Churg - Strauss), microscopic polyangiitis, or polyarteritis nodosa without poor prognosis factors: A randomized, controlled trial. Arthritis Rheumatol. 2017;69:2175-2186. doi: 10.1002/art.40205

19. Metzler C, Miehle N, Manger K, Iking-Konert C, de Groot K, Hellmich B, et al. Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener's granulomatosis. Rheumatology (Oxford). 2007;46:1087-1091. doi: 10.1093/rheumatology/kem029

20. Kado R, Sanders G, McCune WJ. Diagnostic and therapeutic considerations in patients with hypogammaglobulinemia after rituximab therapy (review). Curr Opin Rheumatol. 2017;29:228-233. doi: 10.1097/BOR.0000000000000377

21. Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371:1198-1207. doi: 10.1056/NEJMoa1403290

22. Joshi L, Tanna A, McAdoo SP, Medjeral-Thomas N, Taylor SR, Sandhu G, et al. Long-term outcomes of rituximab therapy in ocular granulomatosis with polyangiitis: Impact on localized and nonlocalized disease. Ophthalmology. 2015;122:1262-1268. doi: 10.1016/j.ophtha.2015.01.016

23. Durel CA, Hot A, Trefond L, Aumaitre O, Pugnet G, Samson M, et al. Orbital mass in ANCA-associated vasculitides: Data on clinical, biological, radiological and histological presentation, therapeutic management, and outcome from 59 patients. Rheumatology (Oxford). 2019;58:1565-1573. doi: 10.1093/rheumatology/Kez071

24. Girard C, Charles P, Terrier B, Bussonne G, Cohen P, Pagnoux C, et al. Tracheobronchial stenoses in granulomatosis with polyangiitis (Wegener's): A report on 26 cases. Medicine (Baltimore). 2015;94:e1088. doi: 10.1097/MD.0000000000001088

25. Sagmeister MS, Grigorescu M, Schonermarck U. Kidney transplantation in ANCA-associated vasculitis. J Nephrol. 2019;32:919-926. doi: 10.1007/s40620-019-00642-x

26. Geetha D, Eirin A, True K, Valentina Irazabal M, Specks U, Seo P, et al. Renal transplantation in antineutrophil cytoplasmic antibody-associated vasculitis: A multicenter experience. Transplantation. 2011;91:1370-1375. doi: 10.1097/TP.0b013e31821ab9aa

27. Sachse F, Stoll W. Nasal surgery in patients with systemic disorders. GMS Curr Top Otorhinolaryngol Head Neck Surg. 2010;9:Doc02. doi: 10.3205/cto000066

28. Congdon D, Sherris DA, Specks U, McDonald T. Long-term follow-up of repair of external nasal deformities in patients with Wegener's granulomatosis. Laryngoscope. 2002;112:731-737. doi: 10.1097/00005537-200204000-00025

29. Tomasson G, Grayson PC, Mahr AD, Lavalley M, Merkel PA. Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis - A meta-analysis. Rheumatology (Oxford). 2012;51(1):100-109. doi: 10.1093/rheumatology/ker280

30. Charles P, Terrier B, Perrodeau E, Cohen P, Faguer S, Huart A, et al. Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: Results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2). Ann Rheum Dis. 2018;77:1143-1149. doi: 10.1136/annrheumdis-2017-212878